Teva Pharmaceutical Industries Ltd (TEVA) SEC filings

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30119% above fair value

$43.24+0.84 (+1.98%)

Close on Nov 11, 2026Market cap $50.39BP/E 72.1Yield –

SEC filings

40 of Teva Pharmaceutical Industries's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 3, 2026	Nov 3, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 3, 2026	SEC EDGAR
Current report	8-K	Oct 27, 2026	Oct 29, 2026	SEC EDGAR
Current report	8-K	Sep 16, 2026	Sep 16, 2026	SEC EDGAR
Current report	8-K	Sep 14, 2026	Sep 14, 2026	SEC EDGAR
Current report	8-K	Sep 9, 2026	Sep 11, 2026	SEC EDGAR
Current report	8-K	Sep 3, 2026	Sep 3, 2026	SEC EDGAR
Current report	8-K	Aug 31, 2026	Sep 3, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Jul 29, 2026	SEC EDGAR
Current report	8-K	Jul 29, 2026	Jul 29, 2026	SEC EDGAR
Current report	8-K	May 28, 2026	May 28, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	Apr 29, 2026	SEC EDGAR
Current report	8-K	Apr 29, 2026	Apr 29, 2026	SEC EDGAR
Proxy statement	DEF 14A	May 28, 2026	Mar 31, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 3, 2026	SEC EDGAR
Current report	8-K	Jan 28, 2026	Jan 28, 2026	SEC EDGAR
Current report	8-K	Jan 11, 2026	Jan 12, 2026	SEC EDGAR
Current report	8-K	Dec 10, 2025	Dec 11, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 5, 2025	SEC EDGAR
Current report	8-K	Nov 5, 2025	Nov 5, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Jul 30, 2025	SEC EDGAR
Current report	8-K	Jul 30, 2025	Jul 30, 2025	SEC EDGAR
Current report	8-K	Jun 5, 2025	Jun 5, 2025	SEC EDGAR
Current report	8-K	May 28, 2025	May 28, 2025	SEC EDGAR
Current report	8-K	May 20, 2025	May 22, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 7, 2025	SEC EDGAR
Current report	8-K	May 7, 2025	May 7, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 5, 2025	Apr 9, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Feb 5, 2025	SEC EDGAR
Current report	8-K	Jan 29, 2025	Jan 29, 2025	SEC EDGAR
Current report	8-K	Nov 5, 2024	Nov 12, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 6, 2024	SEC EDGAR
Current report	8-K	Nov 6, 2024	Nov 6, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Jul 31, 2024	SEC EDGAR
Current report	8-K	Jul 31, 2024	Jul 31, 2024	SEC EDGAR
Current report	8-K	Jun 23, 2024	Jun 25, 2024	SEC EDGAR
Current report	8-K	Jun 6, 2024	Jun 6, 2024	SEC EDGAR
Current report	8-K	May 15, 2024	May 15, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 8, 2024	SEC EDGAR
Current report	8-K	May 8, 2024	May 8, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Teva Pharmaceutical Industries's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Jul 1, 2004
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TEVA.

Compare: TEVA vs VTRS · TEVA vs GRFS · TEVA vs BHC · TEVA vs REGN · TEVA vs AMRX

Revenue growth-15.2% · median 9.8%

Gross margin64.4% · median 37.8%

Operating margin11.4% · median 13.1%

Net margin5.0% · median 4.2%

Company	Revenue	Growth
REGN	$16.90B	+18.6%
VTRS	$14.73B	+4.3%
TEVA	$14.10B	-15.2%
BHC	$11.11B	+10.8%
AMRX	$3.20B	+8.9%
GRFS	–	–

Company

Next earnings (est.): Jan 11, 2027, before open
Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 33,950
Auditor: Kesselman & Kesselman
SEC CIK: 818686

Advertisement
300 × 250

See a number that looks wrong?